Mr. Myron Holubiak will present an update on the Company, including its Phase 3 pivotal trial with Mino-Lok® that is currently more than half enrolled and its option to license a novel stem cell ...

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an ...

Citius Pharmaceuticals CTXR shares tumbled on Friday after the company announced a registered direct offering, a financing move that often pressures micro-cap biotech stocks due to dilution concerns.

Update: Citius Pharmaceuticals announced Aug. 5, 2024, that TenX Keane Acquisition’s shareholders approved their previously announced merger, which is expected to close “in the coming weeks.” Read ...

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares are trading higher Monday after the company announced it entered into a distribution services agreement with Cardinal Health. The Details: Cities ...

This press release and the interview to which it relates may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities ...

Citius Oncology has secured up to $36.5m to accelerate the commercialisation of Lymphir, a recombinant fusion protein immune therapy.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, ...

Interested parties may schedule 1-on-1 meetings with Citius management by registering through the event platform or contacting the Company's investor relations team. Citius Oncology will be meeting ...